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Abstract
Serum concentrations of total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-
density lipoprotein cholesterol (HDL-C), and triglycerides (TG) are among the most important risk
factors for coronary artery disease (CAD) and are targets for therapeutic intervention. We screened
the genome for common variants associated with serum lipids in >100,000 individuals of
European ancestry. Here we report 95 significantly associated loci (P < 5 × 10-8), with 59 showing
genome-wide significant association with lipid traits for the first time. The newly reported
associations include single nucleotide polymorphisms (SNPs) near known lipid regulators (e.g.,
CYP7A1, NPC1L1, and SCARB1) as well as in scores of loci not previously implicated in
lipoprotein metabolism. The 95 loci contribute not only to normal variation in lipid traits but also
to extreme lipid phenotypes and impact lipid traits in three non-European populations (East
Asians, South Asians, and African Americans). Our results identify several novel loci associated
with serum lipids that are also associated with CAD. Finally, we validated three of the novel genes
—GALNT2, PPP1R3B, and TTC39B—with experiments in mouse models. Taken together, our
findings provide the foundation to develop a broader biological understanding of lipoprotein
metabolism and to identify new therapeutic opportunities for the prevention of CAD.
Serum concentrations of total cholesterol (TC), low-density lipoprotein cholesterol, high-
density lipoprotein cholesterol, and triglycerides are heritable risk factors for cardiovascular
disease and targets for therapeutic intervention1. Genome-wide association studies
(GWASs) involving up to 20,000 individuals of European ancestry have identified >30
genetic loci contributing to inter-individual variation in serum lipid concentrations2-10. Half
of these loci harboured genes previously known to influence serum lipid concentrations,
establishing the technical validity of the lipid GWAS. Nevertheless, the practical value of
the GWAS approach remains a subject of debate11-14.
Here we focus on three key questions motivated by recent progress in genetic mapping: (1)
are loci identified in populations of European descent important in non-European groups,
suggesting relevance in different global populations; (2) are these loci of clinical relevance,
providing the framework to identify potential novel drug targets for the treatment of extreme
lipid phenotypes and prevention of coronary artery disease (CAD); and (3) do these loci
harbour genes with biological relevance, i.e., are directly involved in lipid regulation and
metabolism?
We address these questions using several approaches: a genome-wide association screen for
serum lipids in >100,000 individuals of European ancestry; evaluation of mapped variants in
East Asians, South Asians, and African Americans; association testing in individuals with
and without coronary artery disease (CAD); evaluation of genetic variants in patients with
extreme serum lipid concentrations; and genetic manipulation in mouse models.
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Genome-Wide Association Mapping in >100,000 Individuals
To identify additional common variants associated with serum TC, LDL-C, HDL-C, and TG
concentrations, we performed meta-analysis of 46 lipid GWASs (Supplementary Tables
1-4). These studies together comprise >100,000 individuals of European descent (maximum
sample size 100,184 for TC; 95,454 for LDL-C; 99,900 for HDL-C; and 96,598 for TG),
ascertained in the United States, Europe, or Australia. In each study, we used genotyped
single nucleotide polymorphisms (SNPs) and phased chromosomes from the HapMap CEU
(Utah residents with ancestry from northern and western Europe) sample to impute
autosomal SNPs catalogued in the HapMap; SNPs with minor allele frequency (MAF) >1%
and good imputation quality (see Methods) were analysed. A total of ∼ 2.6 million directly
genotyped or imputed SNPs were tested for association with each of the four lipid traits in
each study. For each SNP, evidence of association was combined across studies using a
fixed-effects meta-analysis.
We identified 95 loci that showed genome-wide significant association (P < 5 × 10-8) with at
least one of the four traits tested (Fig. 1; Supplementary Fig. 1; Supplementary Table 2).
These include all of the 36 loci previously reported by GWAS at genome-wide
significance2-10 and 59 loci reported here in a GWAS for the first time. Among these 59
novel loci, 39 demonstrated genome-wide significant association with TC, 22 with LDL-C,
31 with HDL-C, and 16 with TG. Among the 36 known loci, 21 demonstrated genome-wide
significant association with another lipid phenotype in addition to that previously described.
To rule out spurious associations arising as a result of imputation artifact, at nearly all loci
we were able to identify proxy SNPs that had been directly genotyped on Illumina and/or
Affymetrix arrays and confirm each of the associations (Supplementary Table 5). The full
association results for each of the four traits are available at http://www.broadinstitute.org/
mpg/pubs/lipids2010/ or http://www.sph.umich.edu/csg/abecasis/public/lipids2010.
To evaluate whether additional independent association signals existed at each locus, we
performed conditional association analyses for each of the four lipid traits including
genotypes at the lead SNPs for each of the 95 loci as covariates in the association analyses
(see Methods). These analyses identified secondary signals in 26 loci (Supplementary Table
6); when these additional SNPs are combined with the lead SNPs, the total set of mapped
variants explains 12.4% (TC), 12.2% (LDL-C), 12.1% (HDL-C), and 9.6% (TG) of the total
variance in each lipid trait in the Framingham Heart Study, corresponding to ∼25-30% of
the genetic variance for each trait.
Previous studies have suggested sex-specific heritability of lipid traits15. A key challenge in
addressing this issue is evaluating enough men and women to achieve adequate statistical
power for each sex. We re-analysed the GWAS for the four lipid traits separately in women
(n = 63,274) and in men (n = 38,514). Four of the 95 loci identified in the primary analysis
showed significant heterogeneity of effect size (P < 0.0005) between men and women
(Supplementary Table 7). Moreover, an additional five loci had significant association in
only one sex and not in the sex-combined analysis. Two loci associated with HDL-C in the
sex-combined analysis (KLF14 and ABCA8) showed female-specific association with TG
and LDL-C, respectively. The KLF14 locus is a striking example, with rs1562398
significantly associated with TG in women (effect size = −0.046 for the C allele, P = 2 ×
10-12), but not in men (effect size = −0.012, P = 0.05) (Supplementary Fig. 2;
Supplementary Table 7).
To gain insight into how DNA variants in associated loci might influence serum lipid
concentrations, we tested whether the mapped DNA sequence variants regulate the
expression levels of nearby genes (expression quantitative trait loci, or eQTLs) in human
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tissues relevant to lipoprotein metabolism (liver and fat)16. We carried out genotyping and
RNA expression profiling of >39,000 transcripts in three types of human tissue samples
from: liver (960 samples), omental fat (741 samples), and subcutaneous fat (609 samples).
We examined the correlations between each of the lead SNPs at the 95 loci and the
expression levels of transcripts located within 500 kb of the SNP. We pre-specified a
conservative threshold of statistical significance at P < 5 × 10-8. At this threshold, we
identified 38 SNP-to-gene eQTLs in liver, 28 in omental fat, and 19 in subcutaneous fat
(Fig. 1 ; Supplementary Tables 8-10). Some lead SNPs are quite remote from the associated
gene transcripts. For example, rs9987289 (associated with both LDL-C and HDL-C)
correlates with a two-fold change in liver expression of PPP1R3B, yet is 174 kb away from
the gene, which as demonstrated below is likely to be a causal gene. Similarly, rs2972146
(associated with both HDL-C and TG in this study, as well as with insulin resistance and
type 2 diabetes mellitus in a prior study17) correlates with IRS1 expression in omental fat,
despite being located 495 kb away from the gene.
Relevance of GWAS Loci in Non-Europeans
As all of the individuals studied in our primary GWAS were of European ancestry, it
remained unclear if the loci we identified in Europeans are relevant in non-European
individuals. To address this question, we performed additional analyses in cohorts
comprising >15,000 East Asians (Chinese, Koreans, and Filipinos), >9,000 South Asians,
and >8,000 African Americans (Fig. 1; Supplementary Table 11). As a similarly sized
control, we also performed genotyping in a cohort of 7,000 additional Europeans.
In the European group, we found that 35 of 36 lead SNPs tested against LDL-C had the
same direction of association as seen in the primary (>100,000 person) analysis (see
Supplementary Table 12 for explanation); 44 of 47 SNPs for HDL-C; and 29 of 32 SNPs for
TG. Such directional consistency for the three traits is unlikely to be due to chance (P = 5 ×
10-10 for LDL-C; P = 1 × 10-10 for HDL-C; and P = 1 × 10-6 for TG). For further replication
evidence, we performed direct genotyping of a subset of the lead SNPs in two European
cohorts together totalling 12,000 individuals and found that 24 of 26 tested SNPs had the
same direction of association (Supplementary Table 13).
We observed similar proportions in South Asians, with 29 of 32 lead SNPs tested against
LDL-C having the same direction of association as in the primary analysis (P = 1 × 10-6); 35
of 39 SNPs for HDL-C (P = 2 × 10-7); and 24 of 27 SNPs for TG (P = 3 × 10-5). We also
had consistent results with East Asians [LDL-C: 29 of 36, P = 2 × 10-4; HDL-C: 38 of 44, P
= 5 × 10-7; TG: 26 of 28, P = 2 × 10-6], with more modest evidence for replication in
African Americans [LDL-C: 33 of 36, P = 1 × 10-7; HDL-C: 37 of 44, P = 3 × 10-6; TG: 24
of 30, P = 7 × 10-4]. Furthermore, we found that the proportions of SNPs that had the same
direction of association and P < 0.05 were similar in the European, South Asian, and East
Asian replication groups, with smaller proportions in African Americans (Supplementary
Table 12). Of note, for a majority of the loci, there was no evidence of heterogeneity of
effects between the primary European groups and each of the non-European groups
(Supplementary Table 11).
These observations suggest that most (but likely not all) of the 95 lipid loci identified in this
study contribute to the genetic architecture of lipid traits widely across global populations.
They also suggest future studies to localize causal DNA variants by leveraging differences
in linkage disequilibrium (LD) patterns among populations. We evaluated the potential for
fine mapping by comparing the number of SNPs in LD with lead SNPs in three HapMap
populations (Supplementary Table 14). At many loci, only a subset of SNPs in high LD (r2 ≥
0.8) with the lead SNP in HapMap CEU are also in high LD with the lead SNP in HapMap
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YRI (Yoruba in Ibadan, Nigeria) individuals or in the joint JPT+CHB (Japanese in Tokyo,
Japan and Han Chinese in Beijing, China) cohort. Such differential LD patterns can prove
useful to refine association boundaries and prioritize SNPs for functional evaluation, as
demonstrated for the LDL-C-associated locus on chromosome 1p13 (reported in a separate
study in this issue of Nature18).
Clinical Relevance of GWAS Loci
To assess whether the GWAS approach yields clinical insights of potential therapeutic
relevance, we sought to determine which of the lipid-associated lead SNPs are also
associated with CAD in a manner consistent with established epidemiological relationships
(i.e., SNP alleles which increase TC, LDL-C, or TG or that decrease HDL-C should be
associated with increased risk of CAD). Whereas LDL-C is an accepted causal risk factor
for CAD, it is unclear whether HDL-C and/or TG are also causal risk factors. This
uncertainty was reinforced by the failure of a drug that raised HDL-C via CETP inhibition to
reduce the risk of cardiovascular disease19.
Whether other drugs that specifically raise HDL-C or lower TG can reduce CAD risk
remains an open question. In contrast, the most widely marketed drugs for lowering of LDL-
C, statins, have been demonstrated in numerous clinical trials to reduce risk of CAD. Statins
inhibit hydroxy-3-methylglutaryl coenzyme A reductase (the protein product of HMGCR)
and thereby reduce LDL-C and TC levels. We observed that the variant of our lead SNP in
the HMGCR locus that is associated with lower LDL-C levels is also associated with lower
CAD risk (P = 0.004), consistent with the clinical effects of statins. Analogously, common
variants in other lipid-associated loci that are also associated with CAD may implicate genes
at these loci as possible therapeutic targets.
We performed association testing for each of the lead SNPs from this study in 24,607
individuals of European descent with CAD and 66,197 without CAD, with a pre-specified
one-sided significance threshold of P < 0.001 requiring directionality consistent with the
relevant lipid-CAD epidemiological relationship. A limited number of loci met this criterion
(Fig. 1; Supplementary Table 15), with most of them being associated with LDL-C—
consistent with LDL-C being a causal risk factor for CAD.
Four novel CAD-associated loci related specifically to HDL-C or TG but not LDL-C: IRS1
(HDL-C, TG), C6orf106 (HDL-C), KLF14 (HDL-C), and NAT2 (TG). That these loci were
associated with CAD suggests that there may be selective mechanisms by which HDL-C or
TG can be altered in ways that also modulate CAD risk. However, it is also possible that
causal genes in these loci may have pleiotropic effects on non-lipid parameters that are
causal for CAD risk reduction. For example, the major allele of the lead SNP in the IRS1
locus is associated with increased risk of type 2 diabetes mellitus, insulin resistance, and
hyperinsulinemia17, along with decreased HDL-C, increased TG, and increased risk of
CAD; it remains unclear which of the metabolic risk factors are responsible for the increased
CAD risk.
Besides CAD, a second clinically relevant phenotype is hyperlipidemia. We asked whether
the common variants in the 95 associated loci, each with individually small effects on serum
lipids, combine to contribute to extreme lipid phenotypes. We genotyped individuals
identified in three independent studies as having high LDL-C (n = 532, mean 219 mg/dL),
high HDL-C (n = 652, mean 90 mg/dL), or high TG (n = 344, mean 1,079 mg/dL). For each
extreme case group, individuals with low serum LDL-C (n = 532, mean 110 mg/dL), HDL-
C (n = 784, mean 36.2 mg/dL), or TG (n = 144, mean 106 mg/dL) served as control groups.
In each case-control sample set, we calculated risk scores summarizing the number of LDL-
C-, HDL-C-, or TG-raising alleles weighted by effect size.
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For LDL-C, we found that individuals with LDL-C allelic dosage score in the top quartile
were 13 times as likely to have high LDL-C than individuals in the bottom quartile (P = 1 ×
10-14) (Supplementary Fig. 3; Supplementary Tables 16, 17). For HDL-C, individuals in the
top quartile of HDL-C risk score were four times as likely to have high HDL-C than
individuals in the bottom quartile (P = 2 × 10-16). For TG, individuals in the top quartile of
TG risk score were 44 times as likely to be hypertriglyceridemic than individuals in the
bottom quartile (P = 4 × 10-28). These results suggest that the additive effects of multiple
common variants contribute to determining membership in the extremes of a quantitative
trait distribution.
Biological Relevance of GWAS Loci
Whether the GWAS approach can yield biological insights that improve our understanding
of the mechanisms underlying phenotypes such as serum lipid concentrations remains an
open question. Loci identified through GWAS may explain a very small proportion of the
variance in a phenotype through naturally occurring common variants in humans, but they
may have a greater impact through rare variants or when targeted by pharmacological or
genetic intervention.
We surveyed our 95 GWAS loci and asked whether any nearby genes are linked to known
Mendelian lipid disorders. There is remarkable overlap between the loci identified here and
18 genes previously implicated in Mendelian lipid disorders (Supplementary Table 18).
Fifteen of the genes underlying these Mendelian disorders lie within 100 kb of one of our
lead SNPs, including 8 that lie within 10 kb of the nearest lead SNP. In 1,000,000
simulations of 95 randomly drawn SNPs, selected to match our lead SNPs with respect to
MAF and the number of nearby genes, the average simulation showed no overlapping loci
and none showed >8 overlapping loci.
An additional two loci represent well-established drug targets for the treatment of
hyperlipidemia: HMGCR (statins) and NPC1L1 (ezetimibe). Several other loci harbor genes
already appreciated to influence lipid metabolism prior to this study: LPA, which encodes
lipoprotein(a); PLTP, which encodes phospholipid transfer protein; ANGPTL3 and
ANGPTL4, lipoprotein lipase inhibitors; SCARB1, a HDL receptor which mediates
selective uptake of cholesteryl ester; CYP7A1, which encodes cholesterol 7-alpha-
hydroxylase; STARD3, a cholesterol transport gene; and LRP1 and LRP4, members of the
LDL receptor-related protein family. Notably, the protein product of one of the genes
implicated by our study—MYLIP—is a ubiquitin ligase that had no recognized role in lipid
metabolism prior to our study's inception, but has since been independently demonstrated to
be a regulator of cellular LDL receptor levels and is now termed Idol (inducible degrader of
the LDL receptor)20.
GALNT2 (encoding UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 2) is a member of a family of GalNAc-transferases, which
transfer an N-acetyl galactosamine to the hydroxyl group of a serine/threonine residue in the
first step of O-linked oligosaccharide biosynthesis. It is the only gene in the mapped locus
on chromosome 1q42 within 150 kb of the lead SNP (rs4846914), which is located in an
intron of the gene. We therefore reasoned that GALNT2 would be an ideal candidate for
functional validation in a mouse model. We introduced the mouse orthologue Galnt2 into
mouse liver via a viral vector. Liver-specific overexpression of Galnt2 resulted in
significantly lower plasma HDL-C (24% compared to control mice) by 4 weeks (Fig. 2a).
We also performed knockdown of endogenous liver Galnt2 through delivery of an shRNA
via a viral vector. Reduction of the transcript level (∼95% knockdown as determined by
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qRT-PCR) resulted in higher HDL-C levels by 4 weeks (71% compared to control mice)
(Fig. 2b). These observations validate GALNT2 as a biological mediator of HDL-C levels.
We further asked whether eQTL studies could facilitate the identification of causal genes in
loci with multiple genes. Out of several genes surrounding a locus on chromosome 8p23
found to be associated with HDL-C, LDL-C, and TC (Fig. 1), only PPP1R3B [encoding
protein phosphatase 1, regulatory (inhibitor) subunit 3B] was found to have an eQTL in liver
(Supplementary Table 7). The allele associated with increased expression correlated with
lower levels of each of the lipid traits. This eQTL relationship suggests that higher
expression of PPP1R3B will lower plasma lipids. Consistent with this prediction,
overexpression of the mouse orthologue Ppp1r3b in mouse liver via a viral vector resulted in
significantly lower plasma HDL-C levels at two weeks (25%) and four weeks (18%) (Fig.
2c), as well as lower TC levels at two weeks (21%) and four weeks (14%) (data not shown).
Similarly, on a locus on chromosome 9p22 found to be associated with HDL-C, TTC39B
(encoding tetratricopeptide repeat domain 39B) was the only one of several genes in the
locus to exhibit an eQTL in liver (Supplementary Table 7), with the allele associated with
decreased expression correlating with increased HDL-C. Consistent with this eQTL,
knockdown of the mouse orthologue Ttc39b via a viral vector, with 50% knockdown of
transcript as determined by qRT-PCR, resulted in significantly higher plasma HDL-C levels
at four days (19%) and seven days (14%) (Fig. 2d). These data suggest PPP1R3B and
TTC39B as causal genes for lipid regulation. These findings, combined with the
demonstration that SORT1 is a causal gene for LDL-C and is regulated in its expression by a
GWAS SNP (reported in a separate study in this issue of Nature18), support the use of eQTL
studies to prioritize functional validation of GWAS-nominated genes.
Together, these observations establish that some of the identified 95 loci harbour novel bona
fide lipid regulatory genes and suggest that with additional functional studies many, if not
all, of the loci will yield insights into the biological underpinnings of lipid metabolism.
New Biological, Clinical, and Genetic Insights
Through a series of studies, we demonstrate that (1) at least 95 loci across the human
genome harbour common variants associated with serum lipid traits in Europeans; (2) the
loci contribute to lipid traits in multiple non-European populations; (3) some of these loci
are associated not only with lipids but also with risk for CAD; (4) common variants in the
loci combine to contribute to extreme lipid phenotypes; and (5) many of the identified loci
harbour genes that contribute to lipid metabolism, including the novel lipid genes GALNT2,
PPP1R3B, and TTC39B that we validated in mouse models.
It has recently been suggested that conducting genetic studies with increasingly larger
cohorts will be relatively uninformative for the biology of complex human disease,
particularly if initial studies have failed to explain a sizable fraction of the heritability of the
disease in question.11 As the reasoning goes, analysis of a few thousand individuals will
uncover the common variants with the strongest effect on phenotype. Larger studies will
suffer from a plateau phenomenon in which either no additional common variants will be
found or any common variants that are identified will have too small an effect to be of
biological interest.
Our study provides strong empirical evidence against this assertion. We extended a GWAS
for serum lipids from ∼20,000 to ∼100,000 individuals and identified 95 loci (of which 59
are novel) that, in aggregate, explain 10%-12% of the total variance (representing ∼25-30%
of the genetic variance). Even though the lipid-associated SNPs we identified have relatively
small effect sizes, some of the 59 new loci contain genes of clear biological and clinical
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importance—among them LDLRAP1 (responsible for autosomal recessive
hypercholesterolemia), SCARB1 (receptor for selective uptake of HDL-C), NPC1L1
(established drug target), MYLIP (recently characterized regulator of LDL-C), and
PPP1R3B (newly characterized regulator of HDL-C). We expect that future investigations
of the new loci (e.g., resequencing efforts to identify low-frequency and rare variants, or
functional experiments in cells and animal models, as demonstrated for SORT1 in a separate
study reported in this issue of Nature18) will uncover additional important new genes. Thus,
the data presented in this study provide a foundation from which to develop a broader
biological understanding of lipoprotein metabolism and to identify potential new therapeutic
opportunities.
Methods Summary
The full Methods are in Supplementary Information and provide information about: (1)
study samples and phenotypes; (2) genotyping and imputation; (3) genome-wide association
analyses; (4) meta-analyses of directly typed and imputed SNPs; (5) estimation of effect
sizes; (6) conditional analyses of top signals; (7) sex-specific analyses; (8) cis-expression
quantitative trait locus analyses; (9) analyses of lipid-associated SNPs in European and non-
European samples; (10) analyses of lipid-associated SNPs in individuals with and without
CAD; (11) analyses of associated SNPs in patients with extreme LDL-C, HDL-C, or TG
levels; (12) simulation studies to assess overlap between GWAS signals and Mendelian
disease loci; and (13) details of mouse studies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Meta-analysis of plasma lipid concentrations in >100,000 individuals of European
descent
The gene name listed in “Locus” column is either a plausible biological candidate gene in
the locus or the nearest annotated gene to the lead SNP. Listed in “Lead Trait” column is the
lipid trait with best P-value among all four traits. Listed in “Other Traits” are additional lipid
traits with P < 5 × 10-8. Listed in “Alleles/MAF” column are: major allele, minor allele, and
minor allele frequency (MAF) within the combined cohorts included in this meta-analysis
(alleles designated with respect to the “+” strand; Supplementary Table 2). Numbers in
“Effect Size” column are in mg/dL for the lead trait, modeled as an additive effect of the
minor allele. P-values are listed for the lead traits. In the “eQTL” column, “Y” indicates that
lead SNP has an eQTL with at least one gene within 500 kb with P < 5 × 10-8 in at least one
the three tissues tested (liver, omental fat, subcutaneous fat). In the “CAD” column, “Y”
indicates that the lead SNP meets the pre-specified statistical significance threshold of P <
0.001 for association with CAD and being concordant between the direction of lipid effect
and the change in CAD risk. In the “Ethnic” column, “+” indicates concordant effect on lead
trait of the variant between the primary meta-analysis cohort and the European or non-
European group, “−” indicates discordant effect on lead trait, and “?” indicates data not
available for the group; in order, the ethnic groups are European, East Asian, South Asian,
and African American (Supplementary Table 11).
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Figure 2. Effects of altered Galnt2, Ppp1r3b, or Ttc39b expression in mouse liver on plasma lipid
levels
a, b, Overexpression and knockdown of Galnt2. Shown are plasma HDL-C levels at
baseline, 2 weeks, or 4 weeks after injection of viral vectors. n = 6 mice per group. c,
Overexpression of Ppp1r3b. Shown are plasma HDL-C levels at baseline, 2 weeks, or 4
weeks after injection of viral vectors. n = 7 mice per group. d, Knockdown of Ttc39b.
Shown are plasma HDL-C levels at baseline, 4 days, or 7 days after injection of viral
vectors. n = 6 mice per group. Error bars show standard deviations. Because independent
experiments were performed at different times and/or sites, there is variability in baseline
HDL-C levels.
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